On June 29, 2026, one of the most consequential hearings in the history of US cannabis policy, the crucial DEA
Having spent over 30 years in advisory roles in financial markets prior to entering the cannabinoid industry, I lived through
The critical June 29 administrative hearing, set to determine whether the US will extend rescheduling efforts to recreational cannabis, is
For much of the past five years, the cannabis industry has been defined by disappointment. Public equities are down approximately
The US Department of Justice has filed a federal lawsuit seeking $8.3m plus interest from New Jersey-based cannabis multistate operator
Since President Trump issued an executive order to expedite cannabis rescheduling in December 2025, questions over the legal implications of this
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling
US cannabis rescheduling is unlikely to trigger a land grab. Instead, it has the potential to reprice medical intellectual property
As the excitement around President Donald Trump’s executive order to push forward with cannabis rescheduling has faded, the bill is
From the euphoric highs of 2018’s ‘green rush’ to the sharp corrections and structural stasis that have followed, cannabis equities
When Maryland Gov. Wes Moore signed a law on April 22 exempting employee stock ownership plans (ESOPs) from the state’s strict five-year license-hold requirement for cannabis businesses, he opened up an exit strategy for founders.
As the cannabis rescheduling project hangs in the balance, two Republican senators are attempting to ensure that one of its
We won’t spam you
